Floatz logo

Immunoglobulin G1-Kappa, Anti-[Fucosyl-Gm1 (Fucosylated Monosialoganglioside 1)], Homo Sapiens Monoclonal Antibody; H-Gamma1 Heavy Chain Homo Sapiens (1-452) [Vh (Homo Sapiens Ighv3-48*02 (90.7%) -(Ighd) -Ighj3*01 (92.3%) M123>T (117), Cdr-Imgt [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo Sapiens Ighg1*03 (100%), G1M3, Ng1M1 Ch1 R120, Ch3 E12, M14 (Ch1 R120 (219) (123-220), Hinge 1-15 (221-235), Ch2 (236-345), Ch3 E12 (361), M14 (363) (346-450), Chs (451-452)) (123-452)], (225-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1D-16*01 (100%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; Dimer (231-231'':234-234'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho) Cell Line Lacking The Enzyme Alpha-(1,6)-Fucosyltransferase (Fut8), Glycoform Alfa

Small Cell Lung Carcinoma

Explore 277 assets in Small Cell Lung Carcinoma →
Floatz Rating
BB65/100
Confidence
Indicative
v0.2
Sponsor
Bristol-Myers Squibb
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT06646276CT.gov
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
—Recruiting———
NCT04702880CT.gov
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
—Completed———
NCT02949895CT.gov
Study of BMS-986012 in Subjects With Small Cell Lung Caner
—Completed———
NCT02815592CT.gov
Trial of BMS-986012 in Combination With Platinum and Etoposide
—Completed———
NCT02247349CT.gov
BMS-986012 in Relapsed/Refractory SCLC
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65Indicative
Detailed axis rationale is planned and will be published soon.

Same indication · Small Cell Lung Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G1-Kappa, Anti-[Fucosyl-Gm1 (Fucosylated Monosialoganglioside 1)], Homo Sapiens Monoclonal Antibody; H-Gamma1 Heavy Chain Homo Sapiens (1-452) [Vh (Homo Sapiens Ighv3-48*02 (90.7%) -(Ighd) -Ighj3*01 (92.3%) M123>T (117), Cdr-Imgt [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo Sapiens Ighg1*03 (100%), G1M3, Ng1M1 Ch1 R120, Ch3 E12, M14 (Ch1 R120 (219) (123-220), Hinge 1-15 (221-235), Ch2 (236-345), Ch3 E12 (361), M14 (363) (346-450), Chs (451-452)) (123-452)], (225-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1D-16*01 (100%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; Dimer (231-231'':234-234'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho) Cell Line Lacking The Enzyme Alpha-(1,6)-Fucosyltransferase (Fut8), Glycoform Alfa (this asset)Bristol-Myers SquibbP3BB · 65
BenmelstobartYayi HeP4A
Anti-Pd-L1 Monoclonal Antibody Shr-1316Suzhou Suncadia Biopharmaceuticals Co., Ltd.P3BBB
BerzosertibNational Cancer Institute (NCI)P2BBB
Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)P4BBB
EtoposideSichuan UniversityP4BBB
CarboplatinUniversity of Maryland, BaltimoreP4BB
VeliparibCentral European Society for Anticancer Drug ResearchP2BB
hs-20093Shanghai Hansoh Biomedical Co., LtdP3BB

+42 more in the Small Cell Lung Carcinoma cohort

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G1-Kappa, Anti-[Fucosyl-Gm1 (Fucosylated Monosialoganglioside 1)], Homo Sapiens Monoclonal Antibody; H-Gamma1 Heavy Chain Homo Sapiens (1-452) [Vh (Homo Sapiens Ighv3-48*02 (90.7%) -(Ighd) -Ighj3*01 (92.3%) M123>T (117), Cdr-Imgt [8.8.15] (26-33.51-58.97-111)) (1-122) -Homo Sapiens Ighg1*03 (100%), G1M3, Ng1M1 Ch1 R120, Ch3 E12, M14 (Ch1 R120 (219) (123-220), Hinge 1-15 (221-235), Ch2 (236-345), Ch3 E12 (361), M14 (363) (346-450), Chs (451-452)) (123-452)], (225-214')-Disulfide With L-Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1D-16*01 (100%) -Igkj4*01 (100%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')]; Dimer (231-231'':234-234'')-Bisdisulfide, Produced In A Chinese Hamster Ovary (Cho) Cell Line Lacking The Enzyme Alpha-(1,6)-Fucosyltransferase (Fut8), Glycoform Alfa in Small Cell Lung Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g1-kappa-anti-fucosyl-gm1-fucosylated-monosialoganglioside-1-homo-sapiens-monoclonal-antibody-h-gamma1-heavy-chain-homo-sapiens-1-452-vh-homo-sapiens-ighv3-4802-907-ighd-ighj301-923-m123t-117-cdr-imgt-8815-26-3351-5897-111-1-122-homo-sapiens-ighg103-100-g1m3-ng1m1-ch1-r120-ch3-e12-m14-ch1-r120-219-123-220-hinge-1-15-221-235-ch2-236-345-ch3-e12-361-m14-363-346-450-chs-451-452-123-452-225-214-disulfide-with-l-kappa-light-chain-homo-sapiens-1-214-v-kappa-homo-sapiens-igkv1d-1601-100-igkj401-100-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-100-km3-a451-153-v101-191-108-214-dimer-231-231234-234-bisdisulfide-produced-in-a-chinese-hamster-ovary-cho-cell-line-lacking-the-enzyme-alpha-16-fucosyltransferase-fut8-glycoform-alfa-small-cell-lung-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →